Candel Therapeutics (CADL) Stock Price, Quote, News & History | Benzinga

Candel Therapeutics Inc (CADL) Stock Price, Quote, News & History

CADLNASDAQ

Trade with Public

Trade with Public

$8.32

-0.03-0.36%

Last update: Jun 11, 12:49 PM

OverviewNews Earnings Events Options Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$8.35

Close

-

Volume / Avg.

673.97K / 1.79M

Day Range

$8.25 - $8.48

52 Wk Range

4.35 - 9.57

Market Cap

$609.61M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

53

Short Interest

25.17%

Days to Cover

7.64

Recent Candel Therapeutics Inc News

Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data

Candel Therapeutics presented positive phase 3 prostate cancer data showing improved disease-free survival, while analysts maintained bullish expectations on the stock.

Nabaparna Bhattacharya

Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating

Candel Therapeutics ripped higher on Monday after a bullish analyst initiation, underscoring how narrative can outpace fundamentals.

Evette Mitkov

Stock Market Today: Dow Jones, S&P 500 Futures Slip After Weaker-Than-Expected GDP Report—Grail, Candel Therapeutics, Copart In Focus (UPDATED)

(Editor's note: The future prices of benchmark tracking ETFs, the lede, and the headline were updated in the story. Figures from economic reports were added.) U.S. stock futures declined on Friday following the release of key economic data. Futures of all the major benchmark indices ticked lower.

Rishabh Mishra

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-47.73M

Investing Cash Flow (TTM)

-1.23M

Financing Cash Flow (TTM)

151.78M

Free Cash Flow (TTM)

-48.99M

Capital Expenditure (TTM)

-1.26M

Net Change in Cash (TTM)

102.82M

Analyst Trends and Forecast

3

Mar

1

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$465.51M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

4.43

Earnings Yield % (TTM)

-12.11%

Earnings Yield % (FWD)

-10.19%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.88

Company Debt

Total Debt

$47.48M

LT Debt

$47.48M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$9.23M

Total Cash

$194.83M

Debt to Equity

0.36

Issuance of Debt (TTM)

$38.71M

Repayment of Debt (TTM)

-$9.23M

Key Statistics

Open

$8.35

Close

-

Volume / Avg.

673.97K / 1.79M

Day Range

$8.25 - $8.48

52 Wk Range

4.35 - 9.57

Market Cap

$609.61M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

53

Short Interest

25.17%

Days to Cover

7.64

About

Sector

Health Care

Industry

Biotechnology

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Candel Therapeutics (CADL) stock?

A

You can purchase shares of Candel Therapeutics (NASDAQ:CADL) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Candel Therapeutics (CADL) competitors?

A

There are no as such competitors for Candel Therapeutics.

Q

What is the forecast, or price target, for Candel Therapeutics (CADL) stock?

A

Candel Therapeutics has a consensus price target of $18.67.

Q

What is the current price for Candel Therapeutics (CADL)?

A

The stock price for Candel Therapeutics (NASDAQ: CADL) is $8.32 last updated June 11, 2026 at 12:49 PM EDT.

Q

Does Candel Therapeutics (CADL) pay a dividend?

A

There are no upcoming dividends for Candel Therapeutics.

Q

When is Candel Therapeutics (NASDAQ:CADL) reporting earnings?

A

Candel Therapeutics does not have any upcoming earnings scheduled.

Q

Is Candel Therapeutics (CADL) going to split?

A

There is no upcoming split for Candel Therapeutics.

Q

What sector and industry does Candel Therapeutics (CADL) operate in?

A

Candel Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.